Last reviewed · How we verify
IVW-1001 Ophthalmic Eyelid Wipe 0.2%
IVW-1001 Ophthalmic Eyelid Wipe 0.2% is a Small molecule drug developed by IVIEW Therapeutics Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | IVW-1001 Ophthalmic Eyelid Wipe 0.2% |
|---|---|
| Sponsor | IVIEW Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2b Controlled Study of Dosing Techniques - Part B (PHASE2)
- IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IVW-1001 Ophthalmic Eyelid Wipe 0.2% CI brief — competitive landscape report
- IVW-1001 Ophthalmic Eyelid Wipe 0.2% updates RSS · CI watch RSS
- IVIEW Therapeutics Inc. portfolio CI
Frequently asked questions about IVW-1001 Ophthalmic Eyelid Wipe 0.2%
What is IVW-1001 Ophthalmic Eyelid Wipe 0.2%?
IVW-1001 Ophthalmic Eyelid Wipe 0.2% is a Small molecule drug developed by IVIEW Therapeutics Inc..
Who makes IVW-1001 Ophthalmic Eyelid Wipe 0.2%?
IVW-1001 Ophthalmic Eyelid Wipe 0.2% is developed by IVIEW Therapeutics Inc. (see full IVIEW Therapeutics Inc. pipeline at /company/iview-therapeutics-inc).
What development phase is IVW-1001 Ophthalmic Eyelid Wipe 0.2% in?
IVW-1001 Ophthalmic Eyelid Wipe 0.2% is in Phase 2.